Diagnostic comparison of 18F-FDG with 18F-FAPI-74 in Thyroid Cancer patients with TENIS Syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-002904-11-CY

Enrollment

Registered

2021-08-11

Start date

2021-09-23

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Imaging comparison of the drug under investigation on thyroid cancer patients with TENIS syndrome

Interventions

Product Name: AlF-FAPI74 Pharmaceutical Form: Solution for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Thyroid cancer patients with TENIS syndrome Older than 18 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: Pregnant Non-consented Simultaneously other tumors

Design outcomes

Primary

Measure	Time frame
Main Objective: Imaging comparison of the drug under investigation on thyroid cancer patients with TENIS syndrome;Secondary Objective: Quantitative absorption of the tumor. Possibility for a better diagnostic tool.;Primary end point(s): Whether the radiopharmaceuticals under investigation can be of a better use than the already existing one;Timepoint(s) of evaluation of this end point: Once 20 patients have been examined	—

Measure

Time frame

Main Objective: Imaging comparison of the drug under investigation on thyroid cancer patients with TENIS syndrome;Secondary Objective: Quantitative absorption of the tumor. Possibility for a better diagnostic tool.;Primary end point(s): Whether the radiopharmaceuticals under investigation can be of a better use than the already existing one;Timepoint(s) of evaluation of this end point: Once 20 patients have been examined

—

Secondary

Measure	Time frame
Secondary end point(s): N/A;Timepoint(s) of evaluation of this end point: N/A	—

Countries

Cyprus

Contacts

Public ContactKRISTIS VEVIS

GERMAN ONCOLOGY CENTER

kristis.vevis@goc.com.cy+35725208159

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026